WINNIPEG, March 25 /CNW/ - IMRIS Inc. (TSX: IM) (“IMRIS” or the “Company”) today announced that it has received clearance from Australia’s Therapeutic Goods Administration permitting the Company to market its newest products, IMRISNV and IMRIScardio in Australia.
